U.S. markets open in 1 hour 58 minutes
  • S&P Futures

    4,542.75
    +6.25 (+0.14%)
     
  • Dow Futures

    35,572.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    15,380.00
    +39.00 (+0.25%)
     
  • Russell 2000 Futures

    2,288.60
    -0.20 (-0.01%)
     
  • Crude Oil

    84.62
    +0.86 (+1.03%)
     
  • Gold

    1,802.70
    +6.40 (+0.36%)
     
  • Silver

    24.51
    +0.06 (+0.25%)
     
  • EUR/USD

    1.1627
    -0.0019 (-0.16%)
     
  • 10-Yr Bond

    1.6550
    0.0000 (0.00%)
     
  • Vix

    15.90
    +0.89 (+5.93%)
     
  • GBP/USD

    1.3774
    +0.0015 (+0.11%)
     
  • USD/JPY

    113.6690
    +0.2090 (+0.18%)
     
  • BTC-USD

    63,119.43
    +2,328.92 (+3.83%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,234.04
    +29.49 (+0.41%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Johnson & Johnson Expects Covid-19 Vaccine Trial Results Out Soon

·2 min read

Johnson & Johnson announced that it is likely to release the Phase 3 trial results of its Covid-19 vaccine candidate soon as the US pharma company reported its 4Q and FY20 earnings. Shares gained 2.7% and closed at $170.48 on Jan. 26.

“We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon,” Johnson & Johnson’s (JNJ) CEO Alex Gorsky said. “Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come.”

The consumer goods and pharma company posted fourth-quarter earnings of $1.86 per share, which came in ahead of analysts’ estimates of $1.82. Revenue rose 8.3% to $22.5 billion year-on-year during the quarter, beating consensus estimates of $21.7 billion.

Johnson & Johnson said quarterly sales were driven by strong operational year-on-year growth at its pharmaceutical segment and consumer health business which grew 14.6% and 2%, respectively.

“Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” Gorsky said.

Johnson & Johnson also provided FY21 outlook. The company expects adjusted earnings of between $9.40 to $9.60 per share. Sales are projected to be in the range of $90.5 to $91.7 billion. (See JNJ stock analysis on TipRanks)

J.P. Morgan analyst Cory Kasimov expects results from the Phase 3 study of JNJ’s Covid-19 vaccine candidate to be released next week.

“Mgmt was asked about the % of patients in the Ph3 study from South Africa and Brazil in the context of different variants, but details were not disclosed; we note that 17%/14% of clinical trial sites (actively recruiting sites based on clinicaltrials.gov) are in SA/Brazil, respectively, but this is likely not representative of the actual patient breakdown,” Kasimov wrote in a note to investors.

Wall Street analysts are bullish about the stock and the consensus is a Strong Buy with 7 analysts recommending a Buy. The average price target of $190.75 implies almost 12% upside potential to current levels.

Related News:
Verizon Adds Fewer Postpaid Subscribers Than Expected In 4Q; Shares Drop
UPS To Divest Freight Business For $800M; Shares Rise 3%
Tilray To Supply Medical Cannabis To France; Shares Gain 14%

More recent articles from Smarter Analyst: